Search results
Roche (RHHBY) AD Study Failure Puts Spotlight on BIIB & Others
Zacks via Yahoo Finance· 2 years agoThe Alzheimer’s disease (AD) study space witnessed yet another setback with Roche RHHBY announcing...
Should You Buy Roche Holding AG (RHHBY) for a Long-Term Outperformance?
Insider Monkey via Yahoo Finance· 10 months agoFiduciary Management Inc. (FMI), an independent money management firm, released its second quarter...
Pharma Stock Roundup: EU Nod to AZN & RHHBY Drugs, FDA Updates for LLY & MRK
Zacks via Yahoo Finance· 2 years agoRoche's (RHHBY) eye drug, Vabysmo and AstraZeneca's (AZN) asthma drug Tezspire get approval in...
Will Ayvakit Aid Blueprint Medicines (BPMC) Amid Rivalry?
Zacks via Yahoo Finance· 2 years agoBlueprint Medicines (BPMC) expects its lead drug, Ayvakit, which is approved to treat rare cancer...
U.S. stocks waver ahead of retail earnings week
Investing.com via Yahoo Finance· 2 years agoBy Liz Moyer Investing.com -- U.S. stocks were mostly lower in early trading on Monday ahead of a week of earnings from major retailers, including Walmart (NYSE:WMT) and Target (NYSE:TGT), that ...
Sesen Bio (SESN) to Report Q3 Earnings: What's in the Cards?
Zacks via Yahoo Finance· 2 years agoIn the third quarter of 2022 results,we expect investors to focus onSesen Bio’s SESN near-term...
Novartis (NVS) to Focus on US Markets Backed by 8 Key Drugs
Zacks via Yahoo Finance· 2 years agoNovartis (NVS) unveils a new focused strategy with the spotlight on the US markets driven by eight...
Midday movers: Oatly, Tyson Foods, Eli Lilly and more
Investing.com via Yahoo Finance· 2 years agoBy Liz Moyer Investing.com -- Stocks were mixed on Monday as investors awaited earnings reports from the biggest U.S. retailers this week. Here are the midday movers for Nov. 14: Oatly Group ...
Sesen (SESN) Halts Bladder Cancer Drug Development, Stock Down
Zacks via Yahoo Finance· 2 years agoSesen Bio (SESN) decides to pause the development of Vicineum in the United States. It also ended...
AstraZeneca (AZN) Enhertu Receives EU Nod for Expanded Use
Zacks via Yahoo Finance· 2 years agoAstraZeneca (AZN) and partner Daiichi Sankyo's cancer drug, Enhertu, receives EU approval for use in...
